Published On: Thu, Mar 13th, 2014

Court Gives Teva Green Light For Generic Arthritis Drug

A federal judge in Virginia ruled that the patent for Pfizer’s Celebrex expires in May.


A US federal judge in Virginia has given Teva Pharmaceutical Industries Ltd. (NYSE: TEVA; TASE: TEVA) the go-ahead to begin marketing a generic version of arthritis treatment Celebrex after ruling that the drug’s patent expires in May. Pfizer Inc. (NYSE: PFE) had been seeking to extend the patent of the blockbuster drug, which has annual sales of $3 billion, through to December 2015.

Published by Globes [online], Israel business news –

Read more about: , , , ,

Wordpress site Developed by Fixing WordPress Problems